Human Milk Oligosaccharide Synthesis via Enzymatic Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The industrial production of human milk oligosaccharides (HMOs) is hindered by the challenges of accessing structurally defined HMOs in sufficient quantity, due to limitations in chemical synthesis and fermentation approaches.
Innovation Solution
The development of biocatalytic strategies using purified or partially purified enzymes, combined with substrate and process engineering, allows for the efficient synthesis and purification of HMOs through multistep one-pot multienzyme (MSOPME) and stepwise one-pot multienzyme (StOPMe) processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chemical synthesis or fermentation approaches are used to produce HMOs, then production capacity is limited, but the complexity of the synthesis process increases
Solution Approach 1:
The patent divides the complex HMO synthesis into modular enzymatic steps, each catalyzed by specific glycosyltransferases acting on protected lactose substrates. This segmentation allows systematic construction of diverse HMO structures through controlled enzymatic reactions rather than attempting complex one-step syntheses.
Solution Approach 2:
The patent employs systematic variation of protecting groups (benzyl, fluorenylmethyl, acetyl, trifluoroacetyl, Boc, Fmoc) on lactose substrates to control enzymatic recognition and reaction specificity. By changing these chemical parameters, the same enzymatic system can produce diverse HMO structures with different functionalities.
2Quantity of substance
If structurally defined HMOs are produced in sufficient quantity, then research and application progress is enabled, but current methods cannot provide adequate quantity
Solution Approach 1:
The patent performs preliminary protection of lactose hydroxyl groups with specific protecting groups before enzymatic glycosylation. This preliminary action controls the regioselectivity and stereospecificity of subsequent enzymatic steps, ensuring structurally defined HMO products can be produced in sufficient quantity with correct architecture.
Solution Approach 2:
The patent uses protected lactose derivatives as intermediary substrates that guide enzymatic reactions to produce specific HMO structures. These intermediaries with controlled protecting groups enable systematic production of diverse HMOs in quantities sufficient for research and applications.
3Adaptability or versatility
If diverse HMO structures including fucosylated and sialylated derivatives are synthesized, then structural diversity is improved, but purification complexity increases
Solution Approach 1:
The patent introduces different protecting groups at specific locations on the HMO molecules (benzyl, fluorenymethyl at reducing end; acetyl, trifluoroacetyl, Boc, Fmoc on hydroxyl groups). This local differentiation of molecular quality enables purification by exploiting the unique properties of each protecting group combination, simplifying separation of diverse HMO structures.
Solution Approach 2:
The patent employs chromophoric protecting groups (particularly fluorenymethyl and benzyl groups) that provide detectable properties for monitoring and purifying HMO products. These groups enable detection and separation based on their optical properties, simplifying purification of structurally diverse HMOs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high-yield synthesis of diverse HMOs, including fucosylated and sialylated derivatives, up to nonaoses, with efficient tag removal and purification, facilitating quick access to HMOs for research and applications.
Implementation Method 1
Biocatalysis is environmentally friendly, sustainable, highly efficient, and selective for the desired molecular transformation. The development of biocatalytic strategies using purified or partially purified enzymes, combined with substrate and process engineering, allows for the efficient synthesis and purification of HMOs
Data Source
AI summary
New derivatives of human milk oligosaccharides and methods for preparing them are disclosed. Also described herein are hST6GALNAC V and hGCNT2-B variants, along with polynucleotides encoding the variants and host cells comprising the polynucleotides. Further provided herein are reaction mixtures comprising the hST6GALNAC V and hGCNT2-B variants.